8/26/2020 8:11:57 AM
Outlook Therapeutics Reports Topline Results And Positive Proof-of-Concept For ONS-5010 / LYTENAVA From NORSE 1
7/7/2020 8:08:14 AM
Outlook Therapeutics Completes Patient Enrollment In NORSE 2 Clinical Trial For ONS-5010 / LYTENAVA
6/17/2020 8:12:42 AM
Outlook Therapeutics Provides Clinical Update On ONS-5010 / LYTENAVA
4/14/2020 8:25:46 AM
Outlook Therapeutics Provides COVID-19 Impact Update On Impact Of The COVID-19 Pandemic On Status Of NORSE 1 And NORSE 2
2/24/2020 8:07:16 AM
Outlook Therapeutics Reports $10.2 Mln Financings Priced At-The-Market
1/28/2020 8:22:22 AM
Outlook Therapeutics Enters Agreements With BioLexis
12/26/2019 8:04:47 AM
Outlook Therapeutics Completes Previously Announced Warrant Restructuring
12/19/2019 8:13:16 AM
Outlook Therapeutics FY Net Loss Attributable $36.0 Mln Or $1.98 Per Share
8/20/2019 8:06:54 AM
Outlook Therapeutics Completes Patient Enrollment For NORSE 1 A Phase 3 Clinical Trial For ONS-5010 In Wet AMD
7/16/2019 8:17:05 AM
Outlook Therapeutics Doses First Patient In ONS-5010-002 Phase 3 Clinical Trial
4/10/2019 9:13:18 AM
Outlook Therapeutics Prices Public Offering Of 10.34 Mln Common Shares